ARKG241108C28000
- 0.05
- 0.000.00%
ARK Genomic Revolution ETF Newsroom
Adaptive Biotechnologies Raises FY2024 Sales Guidance From $140.00M-145.00M to $143.00M-145.00M
Wells Fargo Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $77
A Closer Look at 4 Analyst Recommendations For Recursion Pharmaceuticals
Here Are the Major Earnings After the Close Today
Where Ionis Pharmaceuticals Stands With Analysts
Intellia Ended The Third Quarter Of 2024 With Approximately $944.7M In Cash, Cash Equivalents And Marketable Securities, The Cash Position Is Expected To Fund Operations Into Late 2026
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target
Recursion Pharmaceuticals Analyst Ratings
Needham Maintains Buy on Veracyte, Raises Price Target to $44
Veracyte Analyst Ratings
Cathie Wood's Wednesday Exodus: Moderna And Jack Dorsey's Block Stocks Get Dumped
Recursion Pharmaceuticals EPS of -$0.34 Misses by $0.01, Revenue of $26.1M Misses by $3.73M
Veracyte Non-GAAP EPS of $0.33 Beats by $0.16, Revenue of $115.86M Beats by $6.03M
RBC Capital Reiterates Sector Perform on CRISPR Therapeutics, Maintains $53 Price Target
Beam Stock Rebounds as Leerink Upgrades Despite Fatality in Gene Editing Trial
A Glimpse of Intellia Therapeutics's Earnings Potential
Ionis Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Announced the Pivotal Phase 3 Study Design Following Alignment With the FDA on ION582 for Angelman Syndrome.
Breaking Down Beam Therapeutics: 5 Analysts Share Their Views
This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday
Beam Therapeutics Analyst Ratings